Argenx (ARGX) is a publicly traded Healthcare sector company. As of May 20, 2026, ARGX trades at $804.59 with a market cap of $48.27B and a P/E ratio of 0.00. ARGX moved +0.83% today. Year to date, ARGX is +0.42%; over the trailing twelve months it is +39.07%. Its 52-week range spans $510.06 to $934.62. Analyst consensus is strong buy with an average price target of $1,017.32. Rallies surfaces ARGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
argenx wins FDA label expansion for VYVGART and Hytrulo across four gMG serotypes: FDA approves VYVGART and VYVGART Hytrulo label expansion to treat adult generalized myasthenia gravis across anti-AChR-Ab, anti-MuSK-Ab, anti-LRP4-Ab and triple seronegative subtypes. Phase 3 ADAPT SERON data showed a 3.35-point mean MG-ADL score improvement at week 4 (p=0.0068) with rapid, sustained symptom relief and consistent safety across serotypes.
| Metric | Value |
|---|---|
| Price | $804.59 |
| Market Cap | $48.27B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $934.62 |
| 52-Week Low | $510.06 |
| Volume | 276.25K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
20 analysts cover ARGX: 0 strong buy, 18 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $1,017.32.